Evolving Concepts in the Diagnosis and Staging of Multiple Myeloma

Presenter: Jens Hillengass

Until recently, treatment for multiple myeloma was only initiated in symptomatic disease. Greater understanding of the underlying biology and the development of new biomarkers, however, has led to changes in diagnosis, and with the help of improved imaging techniques, clinicians are increasingly identifying patients with early myeloma who may benefit from treatment. One major development in diagnostic imaging is the replacement of radiography with CT. PET/CT imaging is also useful for treatment response assessment, because the disappearance of focal lesions is an important prognostic factor. Finally, the Revised International Staging System for multiple myeloma has incorporated additional prognostic markers of aggressive disease, and risk-adapted treatment has been shown to improve survival.

Disclosures: Dr. Hillengass has disclosed that he has received honoraria from Amgen and Janssen, has received grant/research support from Celgene, and is a scientific advisor for Adaptive, Amgen, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen, Oncopeptides, and Oncotracker.

Correspondence: Jens Hillengass, MD, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14214. Email: jens.hillengass@roswellpark.org
  • 1.

    Kyle RA, Remstein ED, Therneau TM, et al.. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:25822590.

  • 2.

    Dispenzieri A, Stewart AK, Chanan-Khan A, et al.. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122:41724181.

  • 3.

    Kastritis E, Moulopoulos LA, Terpos E, et al.. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 2014;28:24022403.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Larsen JT, Kumar SK, Dispenzieri A, et al.. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941946.

  • 5.

    Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365:474475.

  • 6.

    Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538548.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Hillengass J, Moulopoulos LA, Delorme S, et al.. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group [published online August 25, 2017]. Blood Cancer J, doi: 10.1038/bcj.2017.78

    • Search Google Scholar
    • Export Citation
  • 8.

    Palumbo A, Avet-Loiseau H, Oliva S, et al.. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:28632869.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Sonneveld P, Avet-Loiseau H, Lonial S, et al.. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:29552962.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Kumar S, Kaufman JL, Gasparetto C, et al.. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130:24012409.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 731 731 19
PDF Downloads 201 201 16
EPUB Downloads 0 0 0